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ABSTRACT 75 
Objectives: Previous research has indicated that components of the metabolic syndrome (MetS), such 76 
as hyperglycaemia and hypertension, are negatively associated with cognition. However, evidence that 77 
MetS itself is related to cognitive performance has been inconsistent. In this longitudinal study, we 78 
aimed to investigate whether MetS or its components affect cognitive decline in ageing men and whether 79 
any interaction with inflammation existed.     80 
Design: Longitudinal study over a mean of 4.4 (SD ± 0.3) years.  81 
Setting: Multi-centre European male Ageing Study (EMAS).  82 
Participants: Men aged 40-79 years.  83 
Measurements: Cognitive functioning was assessed using the Rey-Osterrieth Complex Figure (ROCF), 84 
the Camden Topographical Recognition Memory (CTRM) task, and the Digit Symbol Substitution Test 85 
(DSST). High-sensitivity C-reactive protein (hs-CRP) levels were measured using a chemiluminescent 86 
immunometric assay.   87 
Results: Overall, 1,913 participants contributed data to the ROCF analyses and 1,965 subjects 88 
contributed to the CTRM and DSST analyses. In multiple regression models, the presence of baseline 89 
MetS was not associated with cognitive decline over time (p>0.05). However, logistic ordinal 90 
regressions indicated that high glucose levels were related to a greater risk of decline on the ROCF Copy 91 
(β=-0.42, p<0.05) and the DSST (β=-0.39, p<0.001). There was neither a main effect of hs-CRP levels 92 
nor an interaction effect of hs-CRP and MetS at baseline on cognitive decline.    93 
Conclusions: We found no evidence for a relationship between MetS or inflammation and cognitive 94 
decline in this sample of ageing men. However, glycaemia was negatively associated with visuo-95 
constructional abilities and processing speed.  96 
 97 
 98 
 99 
 100 
OBJECTIVE  101 
The metabolic syndrome (MetS) is a cluster of cardiovascular risk factors which includes abdominal 102 
obesity, hypertension, hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-c), and 103 
elevated blood glucose levels[1], affecting 20-30% of adults suffering from MetS worldwide[2]. MetS 104 
and its components are associated with a range of negative cardiovascular health outcomes[3]. Emerging 105 
evidence suggests that MetS may also present an increased risk of dementia[4-7] and accelerated decline 106 
of cognitive abilities such as visual working memory[8] and executive functioning[9,10]. However, 107 
while some studies indicate that MetS affects cognition over and above the sum of its individual 108 
components[11,12], not all research has confirmed a synergistic effect of MetS criteria on cognitive 109 
decline. The longitudinal Atherosclerosis Risk in Communities Study found that hypertension and 110 
diabetes mellitus were associated with greater declines in processing speed, verbal memory, and 111 
executive functioning in middle-aged men, whereas MetS as a whole was not[13]. Similarly, prospective 112 
data of 2,476 older adults indicated that risk factors such as hyperinsulinemia and diabetes but not MetS 113 
were associated with an increased risk of developing dementia[14]. Moreover, a large multi-centre study 114 
of 7,087 community-dwelling older adults suggested that MetS does not predict development of 115 
dementia any better than its’ separate components[15]. It is therefore not yet clear whether MetS is a 116 
better predictor of cognitive ageing than its individual components. The relationship between MetS and 117 
cognition may be further complicated by concurrent inflammatory processes, with the first increasing 118 
the latter and vice versa[11]. In people with MetS, some cross-sectional and longitudinal studies have 119 
primarily observed poor cognitive performance[16-18] and mild cognitive impairment[19] in 120 
individuals who present with high serum markers of inflammation. The inflammatory response should 121 
therefore be considered when examining the association between MetS and cognitive ageing. We 122 
present longitudinal findings from the European Male Ageing Study (EMAS), a multi-centre cohort 123 
study of middle-aged and older men[20]. The main objective was to investigate whether baseline MetS 124 
was associated with cognitive decline over time in ageing men. Furthermore, we aimed to examine the 125 
impact of individual MetS components on cognitive ageing. Lastly, we explored potential interaction 126 
effects of MetS and hs-CRP levels, a biomarker of inflammation, on the rate of cognitive decline. 127 
METHODS 128 
Study participants  129 
Recruitment and assessment of participants of the European Male Ageing Study have been described in 130 
detail elsewhere[20]. Briefly, 3,369 community-dwelling men aged 40 to 79 years were recruited from 131 
population and health registers in centres based in Leuven, Belgium; Manchester, UK; Florence, Italy; 132 
Łódź, Poland; Malmö, Sweden; Santiago de Compostela, Spain; Szeged, Hungary; and Tartu, Estonia. 133 
A letter of invitation including a postal questionnaire was sent to gather information about education, 134 
general health, and physical activity. The mean adjusted response rate across the eight centres was 43%. 135 
Men who agreed to partake were invited to attend for physical and cognitive performance measures, an 136 
interviewer-assisted questionnaire, and a fasting blood test. Follow-up assessments took place at a mean 137 
of 4.4 (SD ± 0.3) years after the baseline measurements. Ethical approval was obtained in accordance 138 
with local practice and institutional requirements in each centre. All participants gave their written 139 
informed consent.  140 
Interviewer-assisted questionnaire and anthropometry  141 
The interviewer-assisted questionnaire included the Beck Depression Inventory-II (BDI) for subjective 142 
depressive symptoms[21], the Physical Activity Scale for the Elderly (PASE)[22], and questions 143 
regarding smoking habits, alcohol consumption, and health. Height and weight were measured using 144 
standard, calibrated instruments[20]. Current prescription and non-prescription medication use was self-145 
reported by the participants. 146 
Cardiovascular risk factors  147 
Seated pulse and blood pressure was recorded following a rest period of 5 minutes using an automated 148 
sphygmomanometer (Omron 500I, Omron Healthcare (UK), Ltd Milton Keynes, UK). Waist 149 
circumference was measured three times using anthropometric tape, with the median value being used 150 
for analyses. Morning phlebotomy was performed before 10am to obtain a fasting blood sample. 151 
Analyses of triglyceride and HDL-c levels were performed in local centres with commercially available 152 
enzymatic assays. The presence of metabolic syndrome was determined according to the National 153 
Cholesterol Education Program Adult Treatment Panel-III (ATP-III) definition[1]. Participants were 154 
classified as having MetS if three or more of the following criteria were met: waist circumference >102 155 
cm, fasting triglyceride >1.7 mmol/l, fasting HDL-c <1.03 mmol/l, blood pressure >130/85 mmHg or 156 
current use of anti-hypertensive medication, and fasting glucose >5.6 mmol/l or current use of anti-157 
diabetic medication. Levels of hs-CRP were measured using a solid-phase chemiluminescent 158 
immunometric assay (Immulite 2000 hs-CRP assay; Diagnostics Products Corporation, Siemens, 159 
Deerfield, IL, USA) with a sensitivity of 0.1 g/l. The intra- and inter-assay coefficients of variation were 160 
2.8% and 3.1%, respectively.  161 
Cognitive performance  162 
The EMAS cognitive test battery consisted of four tasks: the Rey-Osterrieth Complex Figure (ROCF) 163 
Copy and Recall, the Camden Topographical Recognition Memory (CTRM) task, and the Digit Symbol 164 
Substitution Test (DSST). The ROCF tasks provide an indication of visuo-constructional abilities and 165 
memory recall[23]. In the Copy component, participants were instructed to copy an abstract figure as 166 
accurately as possible within a 5-minute time limit. In the Recall task, participants were asked without 167 
previous warning to draw the figure from memory thirty minutes after completing the copy. Scoring 168 
criteria were based on the original procedure, with a maximum score of 36 points. The CTRM assesses 169 
visual recognition memory[24] and involves the sequential presentation of photographs of urban scenes 170 
followed by a forced-choice recognition component. One point was given for each correctly identified 171 
image, with a maximum score of 30. Finally, the DSST is a paper-and-pencil subtest from the Wechsler 172 
Adult Intelligence Scale used to measure psychomotor speed and visual scanning[25]. Participants had 173 
to substitute as many symbols for digits as possible within 60 seconds using a coding table.  174 
Statistical analysis  175 
Participants with incomplete cognitive or MetS data at baseline or follow-up were excluded from the 176 
analyses. Characteristics of the study sample at baseline were compared by MetS status using Mann-177 
Whitney U tests for continuous variables and χ2 tests for dichotomous variables. Continuous cognitive 178 
change was calculated by subtracting the baseline score from the follow-up score. In order to specifically 179 
compare participants with significant cognitive decline to those who did not demonstrate cognitive 180 
decline, cognitive change was also investigated as a categorical variable. Participants were divided into 181 
the categories “Decline” (>1 SD decrease from baseline), “No change” (<1 SD change from baseline), 182 
and “Improvement” (>1 SD increase from baseline). Furthermore, we examined the effect of persistent 183 
MetS over time, defined as the presence of MetS at both baseline and follow-up measurements. 184 
Dichotomous variables (absent vs. present) were created for baseline MetS status as well as for the 185 
individual MetS criteria based on the ATP-III definition.     186 
 Age-adjusted linear regressions were performed to examine the relationship between continuous 187 
cognitive decline and MetS. Categorical cognitive decline was investigated using age-adjusted ordinal 188 
logistic regressions. Predictors were baseline MetS status, number of MetS criteria present (0-5), and 189 
individual dichotomised MetS criteria. Subsequently, further adjustments were made for education 190 
(years), BDI score, smoking (non-smoker vs. currently smoking), alcohol consumption (<1 day/week 191 
vs. ≥1 day/week), PASE score, and centre. Finally, analyses were adjusted for the presence of heart 192 
disease and stroke. An interaction term between BDI score and baseline MetS was included to assess 193 
potential moderation effects of depressive symptoms on the relationship between MetS and cognitive 194 
decline, as previous research has indicated that MetS is associated with an increased risk of 195 
depression[26] which can negatively affect cognition[27]. Furthermore, an interaction term between hs-196 
CRP and baseline MetS status was used as a predictor variable to examine the effect of inflammation 197 
on MetS and cognitive decline. Results are expressed as unstandardized beta coefficients (β) and 95% 198 
confidence intervals. Statistical analyses were undertaken using Stata version 13.1 (StataCorp, College 199 
Station, TX, USA).  200 
RESULTS  201 
Cohort characteristics  202 
Of the men who participated in baseline assessments, 2,738 (86.1% of survivors) returned for follow-203 
up measurements. A total of 698 participants was excluded from the analyses due to incomplete MetS 204 
data, resulting in a final cohort of 1,913 participants for the ROCF tests and 1,965 participants for the 205 
CTRM and DSST. Baseline characteristics of the sample by MetS status are shown in Table 1. On 206 
average, participants with MetS at baseline were older, showed more subjective depressive symptoms, 207 
were less physically active, had higher levels of hs-CRP, consumed less alcohol, and were more likely 208 
to have a history of heart disease or diabetes. The prevalence of MetS was 28.8% at baseline and 32.6% 209 
at follow-up. A χ2 test revealed that baseline MetS incidence differed significantly by centre (p <0.001), 210 
ranging from 18.3% in Leuven to 44.2% in Szeged. The most common MetS criterion met was 211 
hypertension (85%), followed by abdominal obesity (35%), hyperglycaemia (33%), 212 
hypertriglyceridaemia (28%), and high HDL-c levels (13%). Mean cognitive scores on the ROCF Recall 213 
and CTRM tasks improved slightly over time, while a decline was observed for the DSST (see Table 2). 214 
A decline of 1SD or more from baseline occurred in 9.0% of participants on the ROCF Copy, 16.0% on 215 
the ROCF Recall, 15.8% on the CTRM, and 20.8% on the DSST. Mann-Whitney tests showed that 216 
participants who were lost to follow-up had lower baseline scores on the ROCF Copy (U = -9.01, p 217 
<0.001), ROCF Recall (U = -8.87, p <0.001), CTRM (U = 6.85, p <0.001), and DSST (U = -11.21, p 218 
<0.001) than those who returned for follow-up. Furthermore, a χ2 test indicated that participants with 219 
MetS at baseline were more likely to be lost to follow-up than those who did not have MetS (p < 0.001).  220 
Metabolic syndrome and cognitive decline  221 
Linear regression models of baseline MetS status, MetS components, and continuous cognitive decline 222 
are summarised in Table 3. In age-adjusted models, MetS, large waist circumference, and high blood 223 
pressure were related to a better performance on the ROCF Recall. Furthermore, hypertriglyceridemia 224 
was associated with a greater decline on the DSST. None of the associations were maintained after 225 
adjusting for confounders such as education, physical activity, and centre. Furthermore, interaction 226 
terms between age or BDI score and MetS or MetS components were not significant for any of the 227 
cognitive tasks (all p >0.05). An increasing number of MetS components was related to better ROCF 228 
and poorer DSST performance in age-adjusted but not fully-adjusted models (see Table 3).  229 
 When cognitive scores were investigated as categorical variables, there was a significant 230 
negative association between baseline MetS and performance on the ROCF Copy and DSST in age-231 
adjusted models (see Table 4). In addition, an increasing number of MetS components was related to a 232 
worsening performance on the ROCF Copy, the CTRM, and the DSST. Of the individual components, 233 
large waist circumference was related to poor performance on the DSST, high glucose levels correlated 234 
with decline on the ROCF Copy, CTRM, and DSST, and high HDL-c was associated with decline on 235 
the ROCF Recall. After adjusting for additional confounders, logistic regressions indicated that the 236 
relationship between glucose levels and decline on the ROCF Copy and DSST remained significant. 237 
When these associations were analysed separately for participants <65 years and participants ≥65 years 238 
at baseline, only the correlation between ROCF Copy change remained significant for older (β = -0.74, 239 
p <0.01) but not younger participants (β = -0.19, p = 0.541). Finally, persistent MetS was associated 240 
with greater decline on the DSST in age-adjusted (β = -1.02, p <0.01) but not fully adjusted models (β 241 
= -0.81, p = 0.225). There were no significant associations between persistent MetS and decline on the 242 
ROCF or CTRM tasks (data not shown). 243 
Cognitive decline and hs-CRP  244 
Baseline hs-CRP levels were not independently associated with decline on any of the four tasks in either 245 
age- or fully-adjusted linear regression models (all p >0.05). Furthermore, there were no significant 246 
interaction effects of hs-CRP and MetS on cognitive performance on either the ROCF Copy (β = -0.37, 247 
p = 0.220), the ROCF Recall (β = -0.32, p – 0.501), the CTRM (β = -0.32, p = 0.317), or the DSST (β = 248 
0.12, p = 0.750).  249 
CONCLUSIONS 250 
In this cohort of ageing European men, we found no evidence for a longitudinal association between 251 
baseline MetS status or the cumulative effect of its components and cognitive decline over a mean period 252 
of 4.4 years. However, hyperglycaemia was associated with an increased risk of decline in visuo-253 
constructional abilities and processing speed. These results are consistent with cross-sectional findings 254 
from the EMAS study that glucose level but not MetS was related to cognitive performance[28]. In 255 
accordance with the present findings, several prospective studies reported no significant correlations in 256 
either middle-aged[13] or older populations[15,29,30]. Although a number of longitudinal studies found 257 
a correlation between MetS and memory[8,10], executive function[10,31], and processing speed[17,30], 258 
effect sizes are generally small[32]. Disparate outcomes in prior studies may in part be caused by 259 
differences in methodology and samples. A meta-analysis of 13 longitudinal studies found that, across 260 
investigations, 17 different tasks were employed to assess cognitive functioning[32], complicating direct 261 
comparisons. In addition, several studies opted for an alternative definition instead of the commonly 262 
used ATP-III guidelines. However, longitudinal studies using the World Health Organisation[33] or 263 
American Heart Association[34] guidelines also reported non-significant associations between MetS 264 
and cognition. Nevertheless, use of alternative diagnostic criteria might yield different results. Finally, 265 
it has been suggested that MetS affects cognition more strongly in women than in men[5,10,15,35,36], 266 
although the reverse pattern has also been observed[18]. Genetic dissimilarities may make women more 267 
vulnerable to the influence of vascular risk factor on the brain than men[15], which could explain the 268 
null findings in our all-male cohort. However, little is known about possible biomechanisms which could 269 
account for a gender-dependent association between MetS and cognition and additional research is 270 
needed.            271 
 While there is thus no conclusive evidence for a relationship between MetS and cognitive 272 
ageing, prior research has frequently reported associations between the individual MetS components 273 
and cognition. While the majority of studies indicates that hyperglycaemia or diabetes[18,20,33,37] and 274 
hypertension[13,18,33,37] in particular are detrimental to cognitive functions, others suggest that HDL-275 
c levels[38] or hypertriglyceridemia[9] are most strongly related to cognitive ageing. The present study 276 
supports previous findings that hyperglycaemia presents a risk factor of cognitive decline, with raised 277 
glucose levels correlating with declines in visuoconstructional abilities and processing speed. Therefore, 278 
hyperglycaemia and/or diabetes may be driving associations between MetS and cognitive decline. 279 
Possible mechanisms by which hyperglycaemia could affect cognitive functions include increases in 280 
early pre-programmed cell death[37] and microvascular disease[38]. Although we found that waist 281 
circumference, blood pressure, and hypertriglyceridemia were also related to ROCF Recall and DSST 282 
performance, these associations were mainly explained by confounding factors. Previous studies which 283 
did not correct for the influence of these confounders may have overestimated the effect of these risk 284 
factors on cognition. Variance in age of the participants from different studies may also explain some 285 
of the conflicting findings, as it has been proposed that the influence of MetS components changes with 286 
age[39]. The present findings suggested that high glucose levels may be particularly detrimental to 287 
cognitive functioning in individuals aged 65 and over. However, we found no other age-related effects 288 
of MetS components on cognition in any of our regression models when including an interaction term 289 
between age and the individual components. Nevertheless, as our sample was relatively young, our 290 
findings may not be comparable to those studies investigating people aged 85 years and over. 291 
 Finally, some studies have indicated that the relationship between MetS and cognition is 292 
modified by inflammation, with the combined presence of MetS and high hs-CRP levels being 293 
associated with greater declines in global cognition[11,18,40] and non-amnestic mild cognitive 294 
impairment[19]. However, we found no evidence of an association between hs-CRP levels, MetS, and 295 
cognitive decline. Once again, this may be due to differences in population characteristics and cognitive 296 
assessments. For example, the longitudinal Sacramento Area Latino Study of Aging (SALSA), which 297 
found that high CRP levels were associated with greater cognitive decline in older adults with MetS 298 
than low CRP levels, used measures of global cognition and verbal abilities to examine cognitive 299 
decline[41]. It is possible that the cognitive tasks used in the present study, which focused on 300 
visuospatial functioning and processing speed, were unable to capture potential interaction effects of 301 
MetS and inflammation. In addition, studies investigating the relationship between CRP, the metabolic 302 
syndrome, and cognition tend to define high and low inflammation based on distributions within the 303 
participant sample [16,42] rather than using a pre-specified value. A wide variety of values has therefore 304 
been used to define ‘high’ inflammation, making it difficult to establish how CRP levels relate to MetS 305 
and cognition. Other biomarkers such as interleukin-6 (IL-6), homocysteine, and α1-antichymotrypsin 306 
may be more strongly correlated with cognitive decline[43]. Alternatively, some studies have used a 307 
combination of inflammatory markers, such as CRP and IL-6 measures, to define high inflammation 308 
rather than investigating the biomarkers in isolation[16]. Future research including or combining other 309 
inflammation biomarkers may contribute to our understanding of the role of inflammation in the 310 
relationship between MetS and cognition.       311 
 Major strengths of EMAS are its prospective and multi-centre design and the broad range of 312 
physiological and performance measures collected. One limitation is that our assessment of cognitive 313 
domains was constrained by the necessary use of culture- and language-fair instruments. We therefore 314 
cannot draw conclusions about the effects of MetS on semantic abilities in men. In addition, performance 315 
on the ROCF and CTRM tasks may be influenced by a practice effect, as underscored by an average 316 
improvement in scores over time, resulting in an underestimation of cognitive decline in our cohort. 317 
However, when we investigated the participants with the greatest cognitive decline in a sub-analysis, 318 
we also did not find a significant association with MetS. As we did not have information about the 319 
presence of MetS prior to our baseline measurements, we were not able to investigate the influence of 320 
any long-term duration of MetS on cognition. However, we found no association between persistent 321 
MetS over 4.4 years and cognitive function. We cannot exclude that a longer duration could be an 322 
important factor in predicting cognitive decline, as a study of middle-aged adults indicated that MetS 323 
was only related to decline in verbal abilities if the syndrome persisted over 10 years[44]. However, the 324 
Caerphilly Prospective Study also found no association between length of MetS exposure and cognitive 325 
performance in a group of middle-aged men over 14 years[35]. It is therefore not yet clear whether the 326 
duration of MetS is related to cognitive decline. As we conducted multiple tests to investigate the 327 
relationship between metabolic syndrome and cognitive decline, there was an increased risk of Type I 328 
errors. Although the results therefore need to be interpreted with caution, the absence of an association 329 
between MetS and cognition in any of our analyses reinforces our conclusion that the syndrome may be 330 
unrelated to cognitive decline. Another limitation to our study is that participants lost to follow-up on 331 
average had lower cognitive scores and were more likely to have MetS. It is therefore possible that 332 
individuals with MetS showing the greatest cognitive impairments were not included in this study. 333 
Moreover, we acknowledge that a relatively small number of participants showed significant cognitive 334 
decline on several of the tasks used. Although we cannot exclude the possibility that the present study 335 
lacked power to investigate associations with cognitive decline, the significant relationships between 336 
cognition and hyperglycaemia suggest that this is not the case. Moreover, several larger prospective 337 
studies have similarly failed to find a relationship between MetS and cognition, providing further 338 
support for our results[13,15,16]. It should be noted that our results are based on a relatively healthy 339 
cohort of European men. As significant associations between MetS and cognitive decline have 340 
previously been reported in other ethnic groups, including Latino [41], Chinese [45], and Korean 341 
participants [46], the present findings should be extrapolated to other populations with care. In addition, 342 
as we did not include measures of mild cognitive impairment or dementia, it is unclear whether the 343 
metabolic syndrome might be associated with more severe cognitive impairments. Finally, although we 344 
adjusted for the influence of alternative factors which may be associated with cognitive decline and 345 
dementia independent of MetS, there are a number of potential predictors which were not investigated 346 
here. For example, risk factors and biomarkers such as the APOE4 allele[47], amyloid load[48], and 347 
hippocampal volume[49] have been related to cognitive decline and risk of dementia in healthy older 348 
adults. We cannot exclude the possibility that factors such as these affected our results. Further research 349 
is needed to clarify the relationship between MetS and dementia syndromes.   350 
CONCLUSION  351 
In view of the large percentage of the population affected by metabolic syndrome, it is important to 352 
understand the consequences of the MetS on general health. Although some previous research suggests 353 
that MetS negatively affects cognition over and above individual cardiovascular risk factors, we did not 354 
find evidence that MetS is related to cognitive decline with age in a large sample of middle-aged and 355 
older European men. Additionally, there was no indication that inflammatory processes worsened 356 
cognitive performance. However, our findings indicate that hyperglycaemia may have a significant 357 
negative effect on several domains of cognitive decline with age. Further research is needed to explore 358 
whether the findings from the EMAS cohort extend to other populations.      359 
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Table 1 Baseline characteristics of the EMAS cohort by baseline MetS status (N = 1,965) 1 
 No MetS 
(n = 1,399 
71.2%) 
MetS  
(n = 566 
28.8%) 
p-value 
       Mean (SD) or %  
Age (years) 58.5 (10.7) 60.0 (10.3) 0.005 
Age left education 
(years) 
21.4 (7.1) 21.9 (8.2) 0.915 
BDI score 6.2 (6.0) 7.2 (6.2) <0.001 
PASE score 212.3 (86.8) 198.6 (92.0) 0.002 
Waist circumference 
(cm) 
94.4 (9.0) 107.0 (9.3) <0.001 
Triglycerides (mmol/l) 1.2 (0.6) 2.0 (0.8) <0.001 
Glucose (mmol/l) 5.3 (0.9) 6.3 (1.5) <0.001 
HDL-c (mmol/l) 1.5 (0.3) 1.2 (0.3) <0.001 
Systolic blood 
pressure (mmHg) 
143.3 (20.2) 151.4 (19.4) <0.001 
Diastolic blood 
pressure (mmHg) 
86.0 (11.7) 90.6 (11.8) <0.001 
Hs-CRP (mg/l) 0.3 (0.7) 0.5 (0.7) <0.001 
Current smoker (%) 19.6 20.1 0.208 
Alcohol consumption 
≥1 day/week (%) 
59.3 54.3 0.044 
Heart condition (%) 14.0 18.4 0.017 
Diabetes (%) 2.8 14.6 <0.001 
Stroke (%) 2.5 4.1 0.064 
Abbreviations: BDI, Beck Depression Inventory; PASE, Physical Activity Scale for the Elderly; hs-2 
CRP, high-sensitivity C-reactive protein. 3 
Table 2 Paired t-tests comparing mean (SD) cognitive performance scores at baseline and follow-up in 1 
EMAS 2 
 N Baseline  Follow-up p-value 
ROCF Copy 1,913 34.0 (3.8) 34.0 (4.0) 0.778 
ROCF Recall 1,913 17.8 (6.4) 18.5 (7.0) <0.001 
CTRM 1,965 23.2 (4.5) 23.5 (4.7) 0.002 
DSST 1,965 29.1 (8.3) 28.2 (8.9) <0.001 
Abbreviations: ROCF, Rey-Osterrieth Complex Figure; CTRM, Camden Topographical Recognition 3 
Memory; DSST, Digit Symbol Substitution Test. 4 
 5 
  6 
1 
 
Table 3 β-coefficients (95% CI) of linear regressions for baseline MetS, number of MetS components, individual criteria, and continuous 
cognitive decline in EMAS 
 ROCF Copy ROCF Recall CTRM DSST 
Model 1a     
Metabolic syndrome 0.13 (-0.23; 0.50) 0.67 (0.10; 1.24)* 0.06 (-0.32; 0.44) -0.29 (-0.74; 0.17) 
Number of MetS components (0 – 5) 0.07 (-0.07; 0.21) 0.32 (0.09; 0.54)** 0.04 (-0.11; 0.18) -0.23 (-0.41; -0.05)* 
Individual criteria     
  Waist circumference >102 cm 0.08 (-0.27; 0.43) 0.61 (0.06; 1.16)* -0.18 (-0.54; 0.18) -0.16 (-0.60; 0.28) 
  Blood pressure >130/85 and/or using anti- 
  hypertensive medication 
0.13 (-0.34; 0.60) 0.98 (0.24; 1.73)* -0.00 (-0.49; 0.48) -0.29 (-0.89; 0.31) 
  Blood glucose >5.6 mmol/l and/or using anti- 
  diabetic medication 
0.28 (-0.08; 0.63) 0.22 (-0.34; 0.78) 0.17 (-0.19; 0.53) 0.39 (-0.83; 0.06) 
  HDL-c <1.03 mmol/l 0.02 (-0.47; 0.50) 0.27 (-0.50; 1.04) 0.35 (-0.16; 0.85) -0.38 (-1.01; 0.24) 
  Triglycerides > 1.5 mmol/l -0.03 (-0.39; 0.34) 0.45 (-0.13; 1.03) 0.08 (-0.30; 0.46) -0.54 (-1.01; -0.08)* 
Model 2b     
Metabolic syndrome 0.05 (-0.33; 0.44) 0.48 (-0.12; 1.07) 0.24 (-0.16; 0.64) 0.04 (-0.43; 0.52) 
Number of MetS components (0 – 5) 0.05 (-0.10; 0.21) 0.16 (-0.07; 0.40) 0.12 (-0.03; 0.28) -0.07 (-0.26; 0.12) 
Individual criteria     
   Waist circumference >102 cm 0.06 (-0.31; 0.42) 0.55 (-0.01; 1.12) -0.01 (-0.39; 0.37) 0.03 (-0.43; 0.49) 
   Blood pressure >130/85 and/or using anti- 
   hypertensive medication 
0.17 (-0.33; 0.67) 0.28 (-0.49; 1.06) 0.12 (-0.40; 0.64) -0.23 (-0.85; 0.39) 
   Blood glucose >5.6 mmol/l and/or using anti- 
   diabetic medication 
0.36 (-0.02; 0.73) 0.08 (-0.50; 0.66) 0.28 (-0.11; 0.67) 0.15 (-0.31; 0.62) 
   HDL-c <1.03 mmol/l -0.24 (-0.77; 0.29) 0.21 (-0.60; 1.03) 0.51 (-0.05; 1.06) -0.10 (-0.76; 0.57) 
   Triglycerides > 1.5 mmol/l -0.07 (-0.46; 0.31) 0.07 (-0.52; 0.67) 0.17 (-0.23; 0.57) -0.43 (-0.91; 0.05) 
Model 3c     
Metabolic syndrome 0.06 (-0.33; 0.45) 0.47 (-0.13; 1.07) 0.24 (-0.16; 0.65) 0.06 (-0.43; 0.54) 
Number of MetS components (0 – 5) 0.06 (-0.09; 0.22) 0.17 (-0.07; 0.40) 0.13 (-0.03; 0.29) -0.06 (-0.25; 0.13) 
Individual criteria     
  Waist circumference >102 cm 0.08 (-0.29; 0.45) 0.56 (-0.01; 1.13) -0.02 (-0.41; 0.37) 0.04 (-0.42; 0.50) 
  Blood pressure ≥130/85 and/or using anti- 
  hypertensive medication 
0.18 (-0.33; 0.68) 0.25 (-0.53; 1.03) 0.16 (-0.36; 0.69) -0.15 (-0.78; 0.47) 
  Blood glucose ≥5.6 mmol/l and/or using anti- 
  diabetic medication 
0.35 (-0.03; 0.72) 0.06 (-0.52; 0.65) 0.29 (-0.10; 0.69) 0.13 (-0.34; 0.60) 
  HDL-c <1-03 mmol/l -0.19 (-0.72; 0.34) 0.22 (-0.60; 1.04) 0.51 (-0.05; 1.07) -0.10 (-0.77; 0.57) 
  Triglycerides ≥ 1.5 mmol/l -0.06 (-0.45; 0.33) 0.11 (-0.49; 0.71) 0.18 (-0.22; 0.59) -0.42 (-0.90; 0.06) 
* p <0.05 ** p <0.01  
aAdjusted for age  
bAdjusted for age, education, BDI score, physical activity, smoking, alcohol consumption, and centre  
cAdjusted for age, education, BDI score, physical activity, smoking, alcohol consumption, centre, and co-morbidities  
Abbreviations: ROCF, Rey-Osterrieth Complex Figure; CTRM, Camden Topographical Recognition Memory; DSST, Digit Symbol Substitution Test; HDL-c, 
high-density lipoprotein cholesterol.  
Table 4 β-coefficients (95% CI) of ordinal logistic regressions of baseline MetS, number of MetS components, individual criteria, and 
categorical cognitive change in EMAS 
 ROCF Copy ROCF Recall CTRM DSST 
Model 1a     
Metabolic syndrome -0.34 (-0.64; -0.03)* -0.06 (-0.26; 0.14) -0.16 (-0.36; 0.04) -0.22 (-0.43; -0.009)* 
Number of MetS components (0 – 5) -0.13 (-0.25; -0.01)* -0.04 (-0.11; 0.04) -0.13 (-0.21; -0.05)** -0.17 (-0.25; -0.09)*** 
Individual criteria     
  Waist circumference >102 cm -0.20 (-0.49; 0.09) -0.02 (-0.21; 0.17) -0.18 (-0.37; 0.01) -0.31 (-0.51; -0.11)** 
  Blood pressure >130/85 and/or using anti- 
  hypertensive medication 
0.34 (-0.07; 0.76) 0.05 (-0.20; 0.31) -0.18 (-0.45; 0.08) -0.14 (-0.41; 0.13) 
  Blood glucose >5.6 mmol/l and/or using anti- 
  diabetic medication 
-0.48 (-0.77; 0.18)** -0.14 (-0.34; 0.05) -0.34 (-0.53; -0.14)** -0.44 (-0.64; -0.24)*** 
  HDL-c <1.03 mmol/l -0.40 (-0.79; 0.00) -0.28 (-0.54; -0.02)* -0.04 (-0.31; 0.23) -0.23 (-0.51; 0.05) 
  Triglycerides >1.5 mmol/l -0.02 (-0.34; 0.30) 0.07 (-0.13; 0.27) -0.17 (-0.37; 0.03) -0.10 (-0.31; 0.11) 
Model 2b     
Metabolic syndrome -0.26 (-0.61; 0.10) -0.02 (-0.23; 0.19) -0.07 (-0.29; 0.14) -0.14 (-0.38; 0.09) 
Number of MetS components (0 – 5) -0.12 (-0.29; 0.05) -0.03 (-0.11; 0.06) -0.03 (-0.12; 0.06) -0.08 (-0.18; 0.01) 
Individual criteria     
  Waist circumference >102 cm -0.18 (-0.58; 0.21) 0.09 (-0.12; 0.30) -0.03 (-0.24; 0.19) -0.16 (-0.40; 0.07) 
  Blood pressure >130/85 and/or using anti- 
  hypertensive medication 
0.56 (0.06; 1.05)* 0.06 (-0.22; 0.33) -0.10 (-0.38; 0.18) -0.05 (-0.35; 0.24) 
  Blood glucose >5.6 mmol/l and/or using anti- 
  diabetic medication 
-0.42 (-0.76; -0.07)* -0.14 (-0.34; 0.07) -0.31 (-0.52; -0.10)** -0.40 (-0.62; -0.17)** 
  HDL-c <1.03 mmol/l -0.30 (-0.88; 0.27) -0.11 (-0.41; 0.20) 0.03 (-0.29; 0.35) -0.10 (-0.44; 0.24) 
  Triglycerides >1.5 mmol/l 0.13 (-0.23; 0.50) 0.09 (-0.12; 0.31) -0.07 (-0.29; 0.15) -0.14 (-0.37; 0.09) 
Model 3c     
Metabolic syndrome -0.25 (-0.61; 0.10) 0.00 (-0.21; 0.22) -0.06 (-0.28; 0.15) -0.13 (-0.36; 0.10) 
Number of MetS components (0 – 5) -0.12 (-0.29; 0.05) -0.02 (-0.11; 0.07) -0.02 (-0.11; 0.07) -0.08 (-0.17; 0.02) 
Individual criteria     
  Waist circumference >102 cm -0.16 (-0.56; 0.24) 0.10 (-0.12; 0.31) -0.02 (-0.23; 0.20) -0.15 (-0.39; 0.08) 
  Blood pressure >130/85 and/or using anti- 
  hypertensive medication 
0.20 (-0.43; 0.83) -0.09 (-0.38; 0.20) 0.01 (-0.28; 0.31) 0.03 (-0.29; 0.34) 
  Blood glucose >5.6 mmol/l and/or using anti- 
  diabetic medication 
-0.42 (-0.77; -0.07)* -0.12 (-0.33; 0.09) -0.31 (-0.52; -0.10) -0.39 (-0.62; -0.17)*** 
  HDL-c <1.03 mmol/l -0.28 (-0.86; 0.29) -0.09 (-0.40; 0.21) 0.04 (-0.28; 0.36) -0.10 (-0.44; 0.24) 
  Triglycerides >1.5 mmol/l 0.11 (-0.25; 0.48) 0.09 (-0.12; 0.31) -0.06 (-0.28; 0.16) -0.13 (-0.36; 0.10) 
* p <0.05 ** p <0.01 *** p <0.001  
aAdjusted for age  
bAdjusted for age, education, BDI score, physical activity, smoking, alcohol consumption, and centre  
cAdjusted for age, education, BDI score, physical activity, smoking, alcohol consumption, co-morbidities, and centre  
Abbreviations: ROCF, Rey-Osterrieth Complex Figure; CTRM, Camden Topographical Recognition Memory; DSST, Digit Symbol Substitution Test; HDL-c, 
high-density lipoprotein cholesterol. 
 
 
 
 
 
